Printer Friendly

Research and Markets: Haemophilus Influenzae Infections - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/zw9qml/haemophilus) has announced the addition of Global Markets Direct's new report "Haemophilus Influenzae Infections - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Haemophilus Influenzae Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections.

- A review of the Haemophilus Influenzae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Haemophilus Influenzae Infections pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Infections.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Infections pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/zw9qml/haemophilus

Source: Global Markets Direct
COPYRIGHT 2013 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 14, 2013
Words:427
Previous Article:Hi-Rel interconnect company Harwin adds Pacent Engineering to cover Metro NY and New Jersey.
Next Article:Research and Markets: Illinois Health Market Review 2012.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters